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OBJECTIVES The aim of this study was to evaluate the relationships between echocardiographic findings
and clinical outcomes in patients with severe primary pulmonary hypertension (PPH).
BACKGROUND Primary pulmonary hypertension is associated with abnormalities of right heart structure and
function that contribute to the poor prognosis of the disease. Echocardiographic abnormal-
ities associated with PPH have been described, but the prognostic significance of these
findings remains poorly characterized.
METHODS Echocardiographic studies, invasive hemodynamic measurements and 6-min walk tests were
performed and outcomes prospectively followed in 81 patients with severe PPH. Subjects
were participants in a 12-week randomized trial examining the effects of prostacyclin plus
conventional therapy compared with conventional therapy alone.
RESULTS During the mean follow-up period of 36.9  15.4 months, 20 patients died and 21 patients
underwent transplantation. Pericardial effusion (p 0.003) and indexed right atrial area (p
0.005) were predictors of mortality. Pericardial effusion (p  0.017), indexed right atrial area
(p  0.012) and the degree of septal shift in diastole (p  0.004) were predictors of a
composite end point of death or transplantation. In multivariable analyses incorporating
clinical, hemodynamic and echocardiographic variables, pericardial effusion and an enlarged
right atrium remained predictors of adverse outcomes. Six-minute walk results, mixed venous
oxygen saturation and initial treatment randomization were also independently associated
with a poor prognosis.
CONCLUSIONS Pericardial effusion, right atrial enlargement and septal displacement are echocardiographic
abnormalities that reflect the severity of right heart failure and predict adverse outcomes in
patients with severe PPH. These characteristics may help identify patients appropriate for
more intensive medical therapy or earlier transplantation. (J Am Coll Cardiol 2002;39:
1214–9) © 2002 by the American College of Cardiology Foundation
Primary pulmonary hypertension (PPH) is a disease char-
acterized by increased pulmonary arterial pressures and
pulmonary vascular resistance. Secondary abnormalities of
right heart structure and function contribute significantly to
the morbidity and mortality associated with the disease
(1,2). As many as two-thirds of the deaths in PPH may be
attributed to right heart failure (2,3). Previously reported
echocardiographic findings in PPH include enlargement,
hypertrophy and decreased contraction of the right ventri-
cle, as well as associated abnormalities of interventricular
septal motion; pericardial effusion; and tricuspid regurgita-
tion (1,4–7). The relationship between echocardiographic
variables and adverse outcomes has been described in only a
few series (7–9).
We examined the associations between echocardio-
graphic findings and clinical outcomes in patients with
severe PPH who were enrolled in a trial of continuous
intravenous prostacyclin. The principal results of the trial
and a description of the effects of prostacyclin on the
echocardiographic manifestations of the disease have been
published previously (4,10). We believe this to be the largest
series of patients with PPH in which well-defined echocar-
diographic data were obtained and outcomes were prospec-
tively followed.
METHODS
Patients. The study sample consisted of 81 patients diag-
nosed with PPH and New York Heart Association
(NYHA) class III or IV symptoms who were enrolled in a
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multicenter, randomized, open-label study examining the
effects of a long-term prostacyclin infusion plus conven-
tional therapy as compared with conventional therapy alone
(10).
Study protocol. The study was approved by the institu-
tional review committee at each participating center, and
informed consent was obtained from each patient before
enrollment. A detailed description of the study protocol has
been reported previously (10).
Patients underwent baseline echocardiography on the
first day of the trial using a predefined imaging protocol (4).
All studies were recorded on VHS videocassettes and were
analyzed at the core echocardiography laboratory using a
digital off-line quantification system. Analyses were per-
formed by a single echocardiographer who was blinded to
the patients’ treatment assignment and clinical information.
For each variable, three representative beats were analyzed
and the mean results calculated. Predefined echocardio-
graphic variables that were analyzed included the following:
1. Right ventricular end-diastolic area (RVEDA) as mea-
sured in the apical four-chamber view by tracing the
endocardial edges of the right ventricle and the plane of
the tricuspid valve at end-diastole. The calculated area
was divided by height to account for differences in body
size.
2. Right ventricular systolic function as estimated by the
right ventricular percent change in area. Areas of the
right ventricle at end-systole (RVESA) and end-diastole
were determined using the method described above, and
the percent change in area calculated as: 100 
(RVEDA  RVESA)/RVEDA.
3. Right atrial area as measured by planimetry in the apical
four-chamber view at end-systole, corrected for height.
4. The eccentricity index, a measure of septal displacement,
measured in the parasternal short-axis view at both
end-systole and end-diastole. This index was calculated
by the method of Ryan et al. (11) as D2/D1, where D2
is the minor-axis dimension of the left ventricle parallel
to the septum and D1 is the minor-axis dimension
perpendicular to and bisecting the septum.
5. Pericardial effusion, defined as a distinct diastolic sepa-
ration of the pericardial layers posterior to the heart on
the parasternal long-axis and short-axis views.
6. Severity of tricuspid regurgitation (TR) quantified as the
ratio of the maximal regurgitant jet area and area of the
right atrium (RA) (TR/RA ratio) in the apical four-
chamber view. The outlines of the regurgitant signal and
the right atrium were traced and the area determined by
computerized planimetry.
7. Maximal instantaneous velocity of the tricuspid regurgi-
tation signal measured using continuous wave Doppler
from the cardiac apex.
Normal values for echocardiographic variables were gen-
erated by analyzing echocardiograms of 40 healthy young
adults without significant cardiopulmonary disease who
participated in an unrelated study.
All patients underwent right heart catheterization as part
of the initial evaluation. Hemodynamic measurements in-
cluded heart rate, mean arterial pressure, mean pulmonary
capillary wedge pressure, mean pulmonary arterial and right
atrial pressures, pulmonary vascular resistance, cardiac index
and mixed venous oxygen saturation. An unencouraged
6-min walk test (12) was performed as an assessment of
exercise capacity.
Patients were randomized to receive either a continuous
infusion of intravenous prostacyclin in addition to conven-
tional therapy or conventional therapy alone for 12 weeks.
Conventional therapy included oxygen, vasodilators, diuret-
ics, cardiac glycosides and anticoagulants, prescribed at the
discretion of the individual investigator. At the conclusion
of the 12-week protocol, all patients were offered the option
of receiving chronic prostacyclin by continuous infusion as
part of an open-label, observational study, and all but five
patients chose this form of therapy. Follow-up data classi-
fying each patient as alive, transplanted or dead was avail-
able for at least 12 weeks in all patients and for at least one
year in 74 of the 81 patients enrolled. The primary end
point examined was all-cause mortality. A composite end
point of death or transplantation was also analyzed.
Data analysis. All analyses were performed using the SAS
statistical software (SAS Institute, Cary, North Carolina).
Data were summarized as mean  SD for continuous
variables and number of subjects (%) for categorical vari-
ables.
Cox proportional hazards modeling was used for univa-
riable analyses of echocardiographic variables as predictors
of death and of the composite end point of death or
transplantation. Baseline clinical, hemodynamic and exer-
cise variables of potential prognostic value, and treatment to
which the patients were randomized were also evaluated.
These included age, gender and NYHA functional class as
clinical variables; heart rate, mean pulmonary arterial and
right atrial pressures, pulmonary vascular resistance, cardiac
index and mixed venous oxygen saturation as hemodynamic
variables; and the distance walked in 6 min as the exercise
variable. Hazard ratios (HRs) and their corresponding 95%
confidence intervals (95% CI) were produced from the
parameter estimates and standard errors obtained from the
proportional hazards models. Kaplan-Meier survival curves
were created for the echocardiographic predictors that had
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statistical significance for the end points; when these pre-
dictors were continuous variables, patients with values above
and below the median were compared.
For the multivariable analyses, an imputed dataset was
produced with the overall mean value imputed for any
missing values so that this dataset contained complete data
for all 81 patients. The multivariable models included all
variables in the echocardiographic, clinical, hemodynamic
and exercise groupings, as well as the initial treatment
randomization. Within each grouping, forward selection
models were fit separately to both the imputed and nonim-
puted datasets to determine the predictors that entered with
two-sided p  0.15. Predictors from each of the groupings
with entry to either of the models for the imputed or
nonimputed datasets were then combined as candidates for
forward selection models on the imputed dataset. Finally,
the resulting models were fit to the nonimputed dataset, and
any nonsignificant predictors were removed.
RESULTS
Baseline demographic features, hemodynamic characteris-
tics and 6-min walk results of the 81 patients are shown in
Table 1. Echocardiographic values are noted in Table 2.
Echocardiograms were of adequate technical quality for
quantification of right ventricular size and function, septal
curvature, pericardial effusion and TR severity in at least 75
patients, and maximal tricuspid regurgitant jet velocity was
measurable in 70. During the follow-up period, 20 patients
died and 21 patients underwent transplantation. Survivors
were followed for a mean of 36.9  15.4 months. Mean
survival in patients who died was 7.5  6.1 months, and
mean time to surgery in patients undergoing transplantation
was 14.4  10.6 months.
The HRs, CIs and significance levels of echocardio-
graphic variables as predictors of adverse outcomes are listed
in Table 3. The presence of a pericardial effusion (p 
0.003) and the right atrial area index (p  0.005) were
significantly associated with mortality. The relationship of
the diastolic eccentricity index with mortality was of mar-
ginal statistical significance (p  0.074). The diastolic
eccentricity index (p  0.004), right atrial area index (p 
0.012) and presence of effusion (p  0.017) were asso-
ciated with the composite end point of death or trans-
plantation. Kaplan-Meier survival curves for significant
echocardiographic predictors of adverse outcomes are
shown in Figure 1.
As illustrated in Table 4, proportional hazards modeling
also demonstrated that death was associated with poor
6-min walk results (p  0.001), high right atrial pressure
(p  0.004), advanced NYHA functional class (p  0.005),
Table 2. Baseline Echocardiographic Variables for the Study




21.2  5.1 (n  75) 10.0  0.4 (n  35)
RV % area change (%) 18.6  8.1 (n  75) 41.5  1.2 (n  35)
RA area index (cm2/m) 19.9  6.6 (n  78) 9.1  1.7 (n  35)
Systolic eccentricity index 1.7  0.4 (n  77) 1.01  0.01 (n  35)
Diastolic eccentricity index 1.9  0.5 (n  77) 1.00  0.01 (n  35)
Pericardial effusion (%) 42 (n  79) 0 (n  40)
TR/RA ratio 0.28  0.17 (n  78) 0.04  0.05 (n  40)
Maximum TR
velocity (m/s)
4.2  0.6 (n  70) Not measured
Data for continuous variables are presented as mean  SD, and values for pericardial
effusion are expressed as the percent of subjects with a significant effusion.
RA  right atrial; RV  right ventricular; TR  tricuspid regurgitation.
Table 1. Clinical Features, Hemodynamic Characteristics and
Exercise Capacity of the 81 Patients
Age (yrs) 40  15
Male gender (n [%]) 22 (27%)
NYHA class IV (n [%]) 21 (26%)
Heart rate (beats/min) 83  15
Mean arterial pressure (mm Hg) 89  11
Mean PCWP (mm Hg) 10  4
Mean PA pressure (mm Hg) 60  13
Mean RA pressure (mm Hg) 12  7
Pulmonary vascular resistance (mm Hg/l/min) 16  7
Cardiac index (l/min) 2.1  0.8
Mixed venous O2 saturation (%) 61  13
6-min walk (ft) 966  413
Data for continuous variables are presented as mean  SD, and values for categorical
values are presented as number (%) of subjects with the stated attribute.
NYHA  New York Heart Association; PA  pulmonary arterial; PCWP 
pulmonary capillary wedge pressure; RA  right atrial.
Table 3. Results of Univariable Proportional Hazards Modeling: Hazard Ratios,
95% Confidence Intervals and p Values for Echocardiographic Variables
Death Composite End Point
HR (95% CI) p Value HR (95% CI) p Value
RV end-diastolic area index (5 cm2/m) 1.34 (0.90–1.98) 0.148 1.26 (0.95–1.66) 0.110
RV % area change (10%) 0.70 (0.39–1.25) 0.225 0.86 (0.57–1.28) 0.454
RA area index (5 cm2/m) 1.54 (1.13–2.10) 0.005 1.33 (1.06–1.66) 0.012
Systolic eccentricity index (0.5 U) 1.41 (0.94–2.13) 0.096 1.20 (0.86–1.68) 0.286
Diastolic eccentricity index (0.5 U) 1.39 (0.97–2.00) 0.074 1.45 (1.12–1.86) 0.004
Pericardial effusion (Y/N) 3.89 (1.49–10.14) 0.003 2.08 (1.12–3.86) 0.017
TR/RA ratio (0.2 U) 1.24 (0.75–2.06) 0.400 1.37 (0.96–1.97) 0.080
Maximum TR velocity (0.5 m/s) 0.90 (0.62–1.31) 0.591 1.00 (0.77–1.30) 0.981
Hazard ratio and confidence interval calculations were based on changes of approximately 1 SD (indicated in parentheses) for
continuous variables and for presence or absence of a pericardial effusion.
CI  confidence interval; HR  hazard ratio; RA  right atrial; RV  right ventricular; TR  tricuspid regurgitation.
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Figure 1. Kaplan-Meier survival curves for echocardiographic predictors of outcomes. By Cox proportional hazards modeling, right atrial (RA) area index (p  0.005) and pericardial effusion (p  0.003)
were significant predictors of death; the relationship of diastolic eccentricity index to mortality was of marginal statistical significance (p  0.074). Right atrial area index (p  0.012), pericardial effusion (p 
















low mixed venous oxygen saturation (p 0.012), high heart
rate (p  0.018) and initial treatment randomization (p 
0.019). Predictors of the composite end point of death or
transplantation were mixed venous oxygen saturation (p 
0.003), right atrial pressure (p 0.013) and distance walked
in 6 min (p  0.023).
Results of the multivariable analysis are shown in Table 5.
Pericardial effusion (p  0.011) was the strongest predictor
of mortality; treatment randomization (p  0.014) and the
distance walked in 6 min (p 0.082) were also independent
predictors. The mixed venous oxygen saturation (p 0.016)
and indexed right atrial area (p  0.106) were independent
predictors of the composite end point of death or transplan-
tation.
DISCUSSION
This study identifies echocardiographic variables associated
with unfavorable outcomes in the largest prospective trial of
patients with PPH yet reported. The right atrial size,
presence of a pericardial effusion and degree of septal shift
were associated with mortality and a composite end point of
death or transplantation. Pericardial effusion and indexed
right atrial area remained significant predictors of adverse
outcomes after accounting for demographic, hemodynamic
and exercise variables.
Significance of the findings. Most deaths in patients with
PPH are due to right heart failure (2,3). The three echo-
cardiographic variables most closely associated with poor
outcomes in our study—right atrial area index, diastolic
eccentricity index and pericardial effusion score—may all be
viewed as indicators of right ventricular decompensation.
In the absence of primary abnormalities of the tricuspid
valve, right atrial enlargement is generally a manifestation of
high right atrial pressure due to functional tricuspid regur-
gitation or elevated right ventricular diastolic pressure, both
consequences of right ventricular failure. In our study
subjects, right atrial area index was closely correlated with
right atrial pressure (r  0.72, p  0.001) and significantly
related to the TR/RA ratio (r  0.33, p  0.01).
Pericardial effusion may also be a manifestation of right
heart failure. The physiology of the formation and removal
of pericardial fluid is incompletely understood. However,
fluid resorption is probably via an extensive venous circula-
tion and a system of lymphatic plexuses that are located in
the subepicardial region of the heart. These ultimately drain
into the RA (13). A previous analysis of our data demon-
strated that effusion size is correlated with right atrial
pressure (9). Thus, it is likely that the pericardial effusion
observed in patients with primary pulmonary hypertension
is due to impaired venous and lymphatic drainage resulting
from elevated right atrial pressure.
An abnormal curvature of the interventricular septum is
considered one of the echocardiographic hallmarks of pul-
monary hypertension (4,6,11,14–16). During diastole the
septum behaves as a passive membrane between the ven-
tricular chambers. When right ventricular diastolic pressure
Table 4. Results of Univariable Proportional Hazards Modeling: Hazard Ratios,
95% Confidence Intervals and p Values for Clinical and Hemodynamic Variables
Death Composite End Point
HR (95% CI) p Value HR (95% CI) p Value
Age (15 yrs) 1.37 (0.86–2.18) 0.187 1.12 (0.82–1.53) 0.468
Male gender (Y/N) 1.76 (0.70–4.41) 0.224 1.36 (0.69–2.67) 0.367
NYHA class IV (Y/N) 3.25 (1.35–7.82) 0.005 1.75 (0.92–3.35) 0.085
Heart rate (15 beats/min) 1.77 (1.10–2.87) 0.018 1.28 (0.93–1.75) 0.131
Mean PA pressure (15 mm Hg) 1.30 (0.76–2.24) 0.344 1.18 (0.80–1.73) 0.406
Mean RA pressure (5 mm Hg) 1.52 (1.13–2.05) 0.004 1.30 (1.05–1.61) 0.013
Pulmonary vascular resistance
(5 mm Hg/l/min)
1.13 (0.82–1.55) 0.458 1.13 (0.91–1.39) 0.261
Cardiac index (1 l/min) 0.80 (0.43–1.48) 0.474 0.66 (0.41–1.07) 0.088
Mixed venous O2 saturation (10%) 0.63 (0.44–0.90) 0.012 0.68 (0.53–0.88) 0.003
6-min walk (500 ft) 0.36 (0.20–0.66) 0.001 0.63 (0.42–0.94) 0.023
Randomization to prostacyclin (Y/N) 0.33 (0.13–0.87) 0.019 0.72 (0.39–1.34) 0.300
Hazard ratio and confidence interval calculations for continuous variables were based on changes of approximately 1 SD
(indicated in parentheses). For categorical variables, HRs and CIs were calculated for presence or absence of the stated attribute.
CI confidence interval; HR hazard ratio; NYHANew York Heart Association; PA pulmonary arterial; RA right
atrial.
Table 5. Results of Multivariable Modeling: Hazard Ratios,
95% Confidence Intervals and p Values for Significant
Multivariable Predictors of Outcome in Models That
Incorporate Echocardiographic, Clinical and
Hemodynamic Variables
HR (95% CI) p Value
Significant multivariable predictors
of death
Pericardial effusion (Y/N) 4.38 (1.41–13.67) 0.011
Randomization to prostacyclin (Y/N) 0.25 (0.08–0.76) 0.014
6-min walk (500 ft) 0.56 (0.29–1.08) 0.082
Significant multivariable predictors
of composite end point
Mixed venous O2 (10%) 0.73 (0.56–0.94) 0.016
RA area index (5 cm2/m) 1.24 (0.96–1.61) 0.106
Hazard ratio and confidence interval calculations were based on the changes indicated
in parentheses for each continuous variable and on the presence or absence of the
stated attribute for categorical variables.
CI  confidence interval; HR  hazard ratio; RA  right atrial.
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is elevated, the septum bulges toward the left ventricle. The
degree of displacement correlates closely with the transeptal
gradient (17) and with mean right atrial pressure (4). During
systole the septal contour is influenced to some extent by
contraction of the septal musculature but, in large part, still
reflects the difference between right and left ventricular pres-
sures. The eccentricity index was originally described by Ryan
et al. (11) as a method of quantifying the septal shift observed
in right ventricular pressure and volume overload states. An
abnormal systolic eccentricity index suggests high pulmonary
arterial systolic pressures. An abnormal diastolic eccentricity
index, the parameter associated with adverse outcomes in our
patients, implies an elevated right ventricular diastolic pressure
and right ventricular failure.
Comparison with previous studies. Previous studies ad-
dressing the relationships between echocardiographic pa-
rameters and clinical outcomes in patients with PPH have
been few in number. Eysmann et al. (7) evaluated the prog-
nostic significance of two-dimensional echocardiographic vari-
ables in an analysis of 26 patients with PPH in which survivors
were followed for a mean of 19.7 months. As in our study,
pericardial effusion size was a significant predictor of mortality,
and this variable remained significant in a multivariable analysis
of echocardiographic and catheterization data.
Several previous studies have identified pulsed wave
Doppler indexes of ventricular filling and right ventricular
contractility that are predictors of mortality. In the analysis
by Eysmann et al. (7), decreased mitral inflow E/A ratio,
shorter pulmonic acceleration time and slower tricuspid
early flow deceleration were associated with poor survival. In
a retrospective study of 53 patients followed at the Mayo
Clinic, a Doppler-derived index combining systolic and
diastolic time intervals was a significant independent pre-
dictor of adverse outcome in patients with PPH (8). Data
necessary for evaluating these Doppler measures were not
prospectively collected in our study.
Study limitations. The use of a composite end point of
death and transplantation is subject to interinstitution variabil-
ity in the criteria for and availability of transplantation. How-
ever, all centers involved were tertiary care facilities with on-site
transplantation available. After the initial 12-week randomized
trial period, all patients were offered prostacyclin therapy, and
all but a few patients went on to receive chronic intravenous
prostacyclin. Because the goal of this study was to examine the
relationship between baseline echocardiographic variables and
outcome, we do not believe the initial period of randomization
significantly altered the results.
Conclusions. Echocardiographic variables can be identi-
fied that predict unfavorable outcomes in patients with
severe PPH. These predictors reflect the severity of right
heart failure and include the indexed right atrial area,
pericardial effusion and degree of septal shift. An assessment
of these variables may help identify patients appropriate for
more intensive medical therapy or earlier transplantation.
As new approaches to treatment of PPH become available
and clinical trials are developed, these variables should be
considered in the analysis of outcome data.
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